An introduction from  51
our management
- Chairman’s Statement
This study highlighted that the patien- the  first  pharmaceutical  company 
- Letter from the CEO
ts’ use and end of life phases are tho- leading the way towards carbon mi-
01 se which contribute the most to CO nimal pMDI solutions that will preser-
2 
Chiesi at a Glance
emissions, with the propellant being  ve patients’ choice and wellbeing by 
02 responsible for more than 90% of to- reducing the carbon footprint of our 
Positive Impacts  tal emissions. This knowledge led us  pMDI by 90%.  es
and Challenges g
n
- Products and Patients to research and develop a new low  le
l
- Processes GWP propellant that enables a drastic  ○ We embrace “sustainable chemi- ha
- Global Value Chain c
- Corporate Citizenship reduction in emissions while safeguar- stry”. Because of the nature of our  nd 
a
ding the effectiveness and the safety  business, we regularly manage che- s 
03 ct
of the product. mical  substances  which  could  be  a
Chiesi’s contribution  p
m
to the UN Sustainable 
harmful to both humans and to the  i
Development Goals e 
v
○ A new low impact generation of  environment.  i
t
i
s
04 F-gases  (Fluorinated  greenhouse  We, therefore, adopted a Sustainable  o
P
Annexes
gases). Chiesi signed the first com- Chemistry Policy so as to eliminate 
- Impact Report
- Data, Methodology  mercial  agreement,  with  propellant  and substitute, as first preference, or 
   and GRI Content Index
gas  supplier  Koura,  to  secure  the  minimise with responsible handling, 
supply of HFA 152a, which is classi- as second, the use of substance of 
fied as a low Global Warming Poten- very high concern (SVHC). The poli-
tial (GWP) propellant, ten times lower  cy foresees the implementation of 
than the currently used, HFA 134a.  processes with effective emissions 
Despite  the  very  limited  contribu- containment strategies; of reduction 
tion of HFAs for pharmaceutical use  systems  with  the  most  innovative 
compared to the total F-gases use,  technologies;  the  avoidance  of  all 
we have committed to a 5-year, €350  molecules that are persistent, bioac-
million  investment  plan,  becoming  cumulative and toxic. 